Day: October 24, 2019

Wintrust Financial Corporation Announces Cash Dividends and Share Repurchase Authorization

Written by Customer Service on October 24, 2019. Posted in Dividend Reports And Estimates.

ROSEMONT, Ill., Oct. 24, 2019 (GLOBE NEWSWIRE) — Wintrust Financial Corporation (“Wintrust” or the “Company”) (Nasdaq: WTFC) today announced that the Company’s Board of Directors approved a quarterly cash dividend of $0.25 per share of outstanding common stock. The dividend is payable on November 21, 2019 to shareholders of record as of November 7, 2019.Additionally, the Company’s Board of Directors approved quarterly cash dividends on outstanding shares of the Company’s 6.50% Fixed-to-Floating Non-Cumulative Perpetual Preferred Stock, Series D. The dividend is payable on January 15, 2020 to shareholders of record as of January 1, 2020.Additionally, the Company’s Board of Directors has authorized the Company to repurchase up to $125 million of its outstanding shares of common stock. “Our decision to authorize a share repurchase...

UFPI Board approves semiannual dividend of $0.20 per share

Written by Customer Service on October 24, 2019. Posted in Dividend Reports And Estimates.

GRAND RAPIDS, Mich., Oct. 24, 2019 (GLOBE NEWSWIRE) — The Board of Directors for Universal Forest Products, Inc. (Nasdaq: UFPI), soon to be UFP Industries, Inc., approved a semiannual dividend payment of $0.20 per share at their October 23, 2019, meeting. The dividend is payable on December 15, 2019, to shareholders of record on December 1, 2019.“I’m thankful for the support of our shareholders, including the many UFPI employees who are invested in our Company and our future,” said Chairman William G. Currie. “I am happy to share the rewards of our success with them through this dividend. We take their investment seriously and are working hard to share even greater rewards in the years to come.”On Wednesday, October 23, 2019, the Company announced record net earnings for the third quarter of 2019.UNIVERSAL FOREST PRODUCTS, INC.Universal...

PhaseBio Expands Executive Management Team

Written by Customer Service on October 24, 2019. Posted in Public Companies.

MALVERN, Pa. and SAN DIEGO, Calif., Oct. 24, 2019 (GLOBE NEWSWIRE) — PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced the expansion of its executive management team with the appointment of Kristopher L. Hanson as Vice President, Head of Legal and Glen Burkhardt as Vice President of Human Resources.“PhaseBio has achieved critical milestones this year and is making solid progress in the advancement of PB2452, a novel agent for the reversal of the antiplatelet activity of ticagrelor,” said Jonathan P. Mow, Chief Executive Officer of PhaseBio. “These additions to our management team allow us to more efficiently prepare for the submission of a Biologics License Application for PB2452...

Enservco Corporation Updates Investors on 2019 Third Quarter Financial Expectations

Written by Customer Service on October 24, 2019. Posted in Public Companies.

DENVER, Oct. 24, 2019 (GLOBE NEWSWIRE) — Enservco Corporation (NYSE American: ENSV), a diversified national provider of specialized well-site services to the domestic onshore conventional and unconventional oil and gas industries, today announced it expects 2019 third quarter revenue to increase approximately 23% year over year to between $4.6 million and $4.7 million from $3.8 million in the third quarter last year. Nine-month revenue is expected to increase approximately 19% to between $38.1 and $38.2 million compared to $32.0 million in the same period last year.Third-quarter adjusted EBITDA loss and net loss are expected to increase year over year. Adjusted EBITDA for the comparative nine-month periods is expected to remain relatively flat, although the year-over-year net loss is expected to improve.“We grew our market share...

Atlantic Capital Bancshares, Inc. Reports Third Quarter 2019 Results

Written by Customer Service on October 24, 2019. Posted in Public Companies.

ATLANTA, Oct. 24, 2019 (GLOBE NEWSWIRE) — Atlantic Capital Bancshares, Inc. (NASDAQ: ACBI) announced net income from continuing operations for the quarter ended September 30, 2019 of $7.6 million, or $0.33 per diluted share, compared to $7.0 million, or $0.27 per diluted share, for the third quarter of 2018 and $7.0 million, or $0.29 per diluted share, for the second quarter of 2019. Diluted earnings per share from continuing operations for the first nine months of 2019 improved to $0.88, an increase of $0.09, or 11%, compared to the first nine months of 2018.“With solid loan and deposit growth from new and expanded client relationships, disciplined expense management, and sound credit quality, Atlantic Capital recorded another quarter of strong operating results,” remarked Douglas Williams, President and Chief Executive Officer.Third...

Frequency Electronics, Inc., Announces MIDS-JTRS Oscillator contract award valued at approximately $4.5 million

Written by Customer Service on October 24, 2019. Posted in Public Companies.

MITCHEL FIELD, N.Y., Oct. 24, 2019 (GLOBE NEWSWIRE) — Frequency Electronics, Inc. (“FEI” or the “Company”) (NASDAQ-FEIM) announced the award of a contract from BAE Systems for precision “g” (acceleration) compensated Oven-controlled Quartz Oscillators (OCXO) for application in the Multifunctional Information Distribution System – Joint Tactical Radio System (MIDS JTRS) radio system. These precision oscillators incorporate FEI’s state-of-the-art, patented technology for operating in high dynamic environments and generate precise frequencies that are critical to the overall performance of the MIDS-JTRS system. The contract is valued at approximately $4.5m.MIDS-JTRS is a four-channel radio designed to run the complex Link 16 waveform and up to three additional communication protocols, including the Airborne Networking Waveform...

DBV Technologies to Highlight the Burden of Peanut Allergy and Patient Experiences with Viaskin Peanut at ACAAI 2019

Written by Customer Service on October 24, 2019. Posted in Public Companies.

Montrouge, France, October 24, 2019DBV Technologies to Highlight the Burden of Peanut Allergy and Patient Experiences with Viaskin Peanut at ACAAI 2019New analysis evaluates quality of life in patients receiving investigational Viaskin PeanutDBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that new analyses on clinical study patient experiences and the significant burden of peanut allergy will be presented at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting in Houston, Texas, November 7-11, 2019. Four abstracts have been accepted, including three oral presentations and one poster presentation.“Peanut allergy places a significant burden on both patients and their families, often due to uncertainty...

DBV Technologies met en exergue la contrainte que représente l’allergie à l’arachide et l’expérience vécue par les patients traités par Viaskin Peanut lors du congrès de l’ACAAI 2019

Written by Customer Service on October 24, 2019. Posted in Public Companies.

Montrouge, France, le 24 octobre (22 h 00 CEST) 2019DBV Technologies met en exergue la contrainte que représente l’allergie à l’arachide et l’expérience vécue par les patients traités par Viaskin Peanut lors du congrès de l’ACAAI 2019De nouvelles analyses évaluent la qualité de vie de patients ayant reçu Viaskin Peanut lors d’études cliniquesDBV Technologies (Euronext : DBV – ISIN : FR0010417345 – Nasdaq : DBVT), une société biopharmaceutique au stade clinique, a annoncé aujourd’hui que de nouvelles analyses sur les expériences vécues par les patients lors des études cliniques et des données sur la contrainte considérable que fait peser l’allergie à l’arachide seront présentées lors du Congrès scientifique annuel de l’American College of Allergy, Asthma & Immunology...

Solid third quarter 2019 performance with strong balance sheet for continued R&D growth

Written by Customer Service on October 24, 2019. Posted in Public Companies.

First nine month financial results:Group revenues of €752.5 millionOperating profit of €393.0 millionNet profit of €265.3 millionCash and cash equivalents on 30 Sept 2019 of €5.6 billionEstablished unique collaboration with Gilead, securing capital and anchoring independent R&D for years to comeFilgotinib submitted by Gilead for approval in RA in Europe and JapanWebcast presentation tomorrow, 25 October 2019, at 14.00 CET/8 AM ET, www.glpg.com, +32 2 404 0659, code 6653712Mechelen, Belgium; 24 October 2019, 22.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announces its unaudited Q3 results, which are further detailed in its Q3 2019 report available on the Galapagos website, www.glpg.com.“There is no question that the third quarter of 2019 was defined by the unique and landmark deal with our long-time...

Sterk derde kwartaal 2019 met solide balans voor verdere R&D-groei

Written by Customer Service on October 24, 2019. Posted in Public Companies.

Financiële resultaten over de eerste negen maanden:Omzet van €752,5 miljoenOperationele winst van €393,0 miljoenNettowinst van €265,3 miljoenKaspositie op 30 september 2019 van €5,6 miljardUnieke samenwerking ondertekend met Gilead, waardoor Galapagos’ financiële slagkracht en onafhankelijke R&D voor jaren is verankerdGoedkeuringsaanvraag voor filgotinib voor de behandeling van reuma ingediend in Europa en JapanWebcast morgen, 25 oktober 2019, om 14.00 CET, www.glpg.com, +32 2 404 0659, code 6653712Mechelen, België; 24 oktober 2019, 22.01 CET; gereglementeerde informatie – Galapagos NV (Euronext & NASDAQ: GLPG) maakt haar niet-geauditeerde resultaten bekend over de eerste negen maanden. Deze resultaten zijn in detail beschreven in het derde kwartaalverslag van 2019, beschikbaar op de Galapagos website, www.glpg.com.“Het derde...

Day: October 24, 2019

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals